Latest news
Business Update
Innosuisse-Funded Alzheimer’s Clinical Trial with MIAMIND®
The MIAMIND® electrical neurostimulator will be evaluated in a randomized, sham-controlled clinical trial in patients with early-stage Alzheimer’s disease (AD), supported by funding from Innosuisse.
08 April, 2026
Read more
Business Update | Wed 02, 2021
Spin-Offs to Watch 2021: BottNeuro on Forbes DACH
Spin-Offs To Watch 2021": Bottneuro AG selected as one of the 30 most promising spin-offs in the DACH region! Bottneuro entwickelt ultradünne Implant
Business Update | Thu 02, 2021
BottNeuro advancing personalized Alzheimer’s therapy
Basel-based startup Bottneuro is working on the development of personalized therapies to treat Alzheimer’s disease in which certain areas of a patient
Business Update | Thu 08, 2019
Gebert Rüf supports NENI project with CHF 300'000.-
NENI – Nano Engineered Neural Interfaces
Featured news
Bottneuro Team
Dr Antonella Santuccione Chadha joins the Board of Directors at Bottneuro
02 June, 2025
